ClinicalTrials.gg
DrugRead study by study

Trastuzumab deruxtecan clinical trials

Also written Enhertu, DS-8201a and DS-8201.

studies test it
120
open now
70
in phase 3
22
first study started
2015
ClinicalTrials.gov finds 231 studies for trastuzumab deruxtecan. How that becomes 120 here

Every study that search finds has been read, to see whether and how it gives trastuzumab deruxtecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 231Found by its intervention search · See all 231 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 152 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −15
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. +4Give it under a name that search misses: a biosimilar’s code or a misspelling
  4. 220Give trastuzumab deruxtecan to participants
  5. −41Observe patients on it, or give it outside a trial
  6. −1Use it as a tool: an imaging tracer or a test of drug response
  7. −8Compare another treatment with it
  8. −50Give it beside what is tested
  9. 120Test it: the count on this site

Get an email when these change. Save the trastuzumab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Dec 2019 · ENHERTU · BLA 761139 (FDA, Drugs@FDA)
European Union
18 Jan 2021 · Enhertu · EMEA/H/C/005124 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Trastuzumab deruxtecan
70
T-DXd
39
Fam-trastuzumab Deruxtecan-nxki
13
Trastuzumab deruxtecan (T-DXd)
5
DS-8201a; T-DXd
4

Brand

Enhertu
36

Development codes

DS-8201a
36
DS-8201
10
WHO 10516
9

Studies by the year they started

116 studies that test it; most in 2025 (24); 4 more planned to start later

Studies that test trastuzumab deruxtecan, by start year
YearStudies
20151
20161
20174
20189
20192
202013
202111
20225
202313
202416
202524
202617

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
24
Phase 2
80
Phase 3
22
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 49 · Other 71

AstraZeneca (21) · Daiichi Sankyo (20) · National Cancer Institute (NCI) (7) · Daiichi Sankyo Co., Ltd. (5) · Fudan University (5) · MedSIR (4) · UNICANCER (4) · Yonsei University (4)

Often tested with

Tested in the same studies.

Pertuzumab (5) · Rilvegostomig (5) · Trastuzumab (5) · Capecitabine (5) · Sacituzumab govitecan (5) · Nivolumab (4) · Tucatinib (4) · Olaparib (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Trastuzumab deruxtecan is the comparator. A study of two new drugs counts under both.

  • 1Apatinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Mar 2031
  • 1Patritumab deruxtecan · Merck Sharp & Dohme LLC · next primary completion Jul 2033
New treatments tested with it · 8 most studied

New when their studies opened, with trastuzumab deruxtecan beside them; studies of each.

Reaching primary completion within a year · 28, 2 in phase 3

Studies that test trastuzumab deruxtecan, phase 3 first.

Studies

Open first, then newest update. How each study uses trastuzumab deruxtecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 120

See all 120 studies that test trastuzumab deruxtecan →

Behind its US label · 13 — the studies the FDA label of ENHERTU describes

From the Clinical Studies section of ENHERTU (2026-05), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 52 — no other medicine in its arm

Showing 20 of 52. See all 52 →

Tested with established drugs · 16 — they are given beside it
Tested in a combination · 52 — another drug in the study is under test too

Showing 20 of 52. See all 52 →

Beside an established treatment under test · 4 — an approved drug, surgery or radiation is what the study tests

Tested with trastuzumab deruxtecan: HER2-targeted Therapy 1 · Trastuzumab 1 · Surgery or a procedure 1 · Radiation 1 · neratinib 1 · Bevacizumab 1 · Hydroxychloroquine 1

Beside a new treatment under test · 33 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with trastuzumab deruxtecan: ivonescimab 3 · SGN-LIV1A 2 · zanidatamab 2 · dulpatatug 2 · ceralasertib 1 · AZD5305 1 · valemetostat 1 · SIRP-alpha-Fc Fusion Protein HCB101 1

Showing 20 of 33. See all 33 →

Beside supportive care · 13 — a supportive treatment or test is studied
As the comparator · 8 — what is tested is compared with trastuzumab deruxtecan
Observed · 41 — patients on it are followed, or it is given outside a trial

Showing 20 of 41. See all 41 →

As a tool · 1 — an imaging tracer or a test of drug response

Codes

What other systems call trastuzumab deruxtecan · ClinicalTrials.gg INT000605

  • MeSH (NLM) C000614160trastuzumab deruxtecanConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 5384HK7574TRASTUZUMAB DERUXTECANConfirmed FDA, NLM, Wikidata
  • RxNorm 2267582One source FDA
  • Wikidata Q80109553trastuzumab deruxtecanConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C128799Trastuzumab DeruxtecanOne source FDA
  • DrugBank DB14962One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion